{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:25:28Z","timestamp":1794029128194,"version":"4.8.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,10,8]],"date-time":"2027-10-08T00:00:00Z","timestamp":1822953600000},"content-version":"am","delay-in-days":280,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016991","name":"Universidad de Guadalajara","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016991","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS114066"],"award-info":[{"award-number":["R01NS114066"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.neuropharm.2026.111216","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:59:00Z","timestamp":1791356340000},"page":"111216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["4-methyl-3-aminopyridine: A novel active blocker of voltage-gated potassium ion channels in the central nervous system"],"prefix":"10.1016","volume":"302","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6807-7059","authenticated-orcid":false,"given":"Sofia","family":"Rodr\u00edguez-Rangel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar Guti\u00e9rrez","family":"Coronado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5259-7336","authenticated-orcid":false,"given":"Brenda Mata","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2880-2556","authenticated-orcid":false,"given":"Saadi","family":"El-Saadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7455-2743","authenticated-orcid":false,"given":"Pedro","family":"Brugarolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8747-7239","authenticated-orcid":false,"given":"Jorge E.","family":"S\u00e1nchez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2026.111216_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejps.2015.05.008","article-title":"Setup and validation of shake-flask procedures for the determination of partition coefficients (logD) from low drug amounts","volume":"76","author":"Andres","year":"2015","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111216_bib2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0006-3495(01)75749-9","article-title":"A model for 4-aminopyridine action on K channels: similarities to tetraethylammonium ion action","volume":"81","author":"Armstrong","year":"2001","journal-title":"Biophys. J."},{"issue":"2037","key":"10.1016\/j.neuropharm.2026.111216_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1126\/science.79.2037.38","article-title":"The method of probits","volume":"79","author":"Bliss","year":"1934","journal-title":"Science"},{"issue":"6621","key":"10.1016\/j.neuropharm.2026.111216_bib4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1126\/science.add8980","article-title":"Halogenation of the 3-position of pyridines through Zincke imine intermediates","volume":"378","author":"Boyle","year":"2022","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111216_bib5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41598-017-18747-3","article-title":"Development of a PET radioligand for potassium channels to image CNS demyelination","volume":"8","author":"Brugarolas","year":"2018","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.neuropharm.2026.111216_bib6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00894-007-0184-9","article-title":"Molecular docking study of the binding of aminopyridines within the K+ channel","volume":"13","author":"Caballero","year":"2007","journal-title":"J. Mol. Model."},{"issue":"6","key":"10.1016\/j.neuropharm.2026.111216_bib7","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/S0026-895X(25)10596-8","article-title":"Aminopyridine block of Kv1.1 potassium channels expressed in mammalian cells and Xenopus oocytes","volume":"45","author":"Castle","year":"1994","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111216_bib8","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000976","article-title":"Neuroprotective properties of 4-Aminopyridine","volume":"8","author":"Dietrich","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"10.1016\/j.neuropharm.2026.111216_bib9","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1007\/s10072-023-06795-9","article-title":"Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis","volume":"44","author":"Ghorbanpour","year":"2023","journal-title":"Neurol. Sci."},{"issue":"9665","key":"10.1016\/j.neuropharm.2026.111216_bib10","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":"Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial","volume":"373","author":"Goodman","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2026.111216_bib11","doi-asserted-by":"crossref","DOI":"10.1021\/acschemneuro.0c00791","article-title":"Radiochemical synthesis and evaluation in non-human Primates of 3-[(11)C]methoxy-4-aminopyridine: a novel PET tracer for imaging potassium channels in the CNS","author":"Guehl","year":"2021","journal-title":"ACS Chem. Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2026.111216_bib12","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1177\/0271678X20963404","article-title":"Evaluation of the potassium channel tracer [(18)F]3F4AP in rhesus macaques","volume":"41","author":"Guehl","year":"2021","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.neuropharm.2026.111216_bib46","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1124\/pr.57.4.10","article-title":"International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels","volume":"57","author":"Gutman","year":"2005","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111216_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1085\/jgp.78.1.63","article-title":"Effects of 4-aminopyridine on potassium currents in a molluscan neuron","volume":"78","author":"Hermann","year":"1981","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.neuropharm.2026.111216_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1113\/jphysiol.1991.sp018421","article-title":"On the active form of 4-aminopyridine: block of K+ currents in rabbit Schwann cells","volume":"433","author":"Howe","year":"1991","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuropharm.2026.111216_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/35036198","article-title":"Neuronal KCNQ potassium channels: physiology and role in disease","volume":"1","author":"Jentsch","year":"2000","journal-title":"Nat. Rev. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111216_bib15","first-page":"CD003279","article-title":"Treatment for Lambert-Eaton myasthenic syndrome","volume":"2011","author":"Keogh","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111216_bib16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0006-3495(78)85503-9","article-title":"3,4-diaminopyridine. A potent new potassium channel blocker","volume":"22","author":"Kirsch","year":"1978","journal-title":"Biophys. J."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111216_bib17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0896-6273(93)90154-J","article-title":"Segmental exchanges define 4-aminopyridine binding and the inner mouth of K+ pores","volume":"11","author":"Kirsch","year":"1993","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2026.111216_bib18","first-page":"222","article-title":"The ability of 4-aminopyridine and 3, 4-diaminopyridine to cross the blood-brain barrier can account for their difference in toxicity","volume":"35","author":"Lemeignan","year":"2013","journal-title":"Adv. Biosci."},{"key":"10.1016\/j.neuropharm.2026.111216_bib19","first-page":"CD003279","article-title":"Treatment for Lambert-Eaton myasthenic syndrome","volume":"2","author":"Maddison","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111216_bib20","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1124\/jpet.123.001773","article-title":"Aminopyridines restore ventilation and reverse respiratory acidosis at late stages of botulism in mice","volume":"388","author":"McClintic","year":"2024","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"23","key":"10.1016\/j.neuropharm.2026.111216_bib21","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","article-title":"3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome","volume":"321","author":"McEvoy","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2026.111216_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.1034730","article-title":"Functional improvement in individuals with chronic spinal cord injury treated with 4-aminopyridine: a systematic review","volume":"13","author":"Paredes-Cruz","year":"2022","journal-title":"Front. Neurol."},{"issue":"15","key":"10.1016\/j.neuropharm.2026.111216_bib23","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.bpj.2025.06.029","article-title":"Voltage gating and 4-aminopyridine inhibition in the Shaker Kv channel revealed by a closed-state model","volume":"124","author":"Pinto-Anwandter","year":"2025","journal-title":"Biophys. J."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111216_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1570-0232(02)00914-5","article-title":"Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in liquid chromatography-tandem mass spectrometry","volume":"785","author":"Polson","year":"2003","journal-title":"J. Chromatogr., B: Anal. Technol. Biomed. Life Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111216_bib25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2967\/jnumed.124.268242","article-title":"Imaging demyelinated axons after spinal cord injuries with PET tracer [(18)F]3F4AP","volume":"66","author":"Ramos-Torres","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.neuropharm.2026.111216_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/08977151261438980","article-title":"Imaging traumatic brain injuries in mice with potassium channel PET tracer [(18)F]3F4AP","author":"Ramos-Torres","year":"2026","journal-title":"J. Neurotrauma"},{"issue":"10","key":"10.1016\/j.neuropharm.2026.111216_bib27","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1039\/D0MD00190B","article-title":"Syntheses of [(11)C]2- and [(11)C]3-trifluoromethyl-4-aminopyridine: potential PET radioligands for demyelinating diseases","volume":"11","author":"Ramos-Torres","year":"2020","journal-title":"RSC Med. Chem."},{"issue":"6 Pt 1","key":"10.1016\/j.neuropharm.2026.111216_bib28","doi-asserted-by":"crossref","first-page":"C1589","DOI":"10.1152\/ajpcell.1994.267.6.C1589","article-title":"Aminopyridine inhibition and voltage dependence of K+ currents in smooth muscle cells from cerebral arteries","volume":"267","author":"Robertson","year":"1994","journal-title":"Am. J. Physiol."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111216_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41598-019-56245-w","article-title":"Structure-activity relationship studies of four novel 4-aminopyridine K(+) channel blockers","volume":"10","author":"Rodriguez-Rangel","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2026.111216_bib45","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-020-0188-7","article-title":"Inherited cardiac arrhythmias","volume":"6","author":"Schwartz","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"5747","key":"10.1016\/j.neuropharm.2026.111216_bib30","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/283570a0","article-title":"Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres","volume":"283","author":"Sherratt","year":"1980","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.neuropharm.2026.111216_bib31","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.ejmech.2005.04.017","article-title":"Development of novel 4-aminopyridine derivatives as potential treatments for neurological injury and disease","volume":"40","author":"Smith","year":"2005","journal-title":"Eur. J. Med. Chem."},{"issue":"Pt 1","key":"10.1016\/j.neuropharm.2026.111216_bib32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/brain\/123.1.171","article-title":"Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension","volume":"123","author":"Smith","year":"2000","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111216_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1212\/CPJ.0000000000000321","article-title":"Aminopyridines for the treatment of neurologic disorders","volume":"7","author":"Strupp","year":"2017","journal-title":"Neurol., Clin. Pract."},{"issue":"23","key":"10.1016\/j.neuropharm.2026.111216_bib34","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1021\/acschemneuro.2c00364","article-title":"Radiochemical synthesis and evaluation of 3-[(11)C]Methyl-4-aminopyridine in rodents and nonhuman Primates for imaging potassium channels in the CNS","volume":"13","author":"Sun","year":"2022","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111216_bib35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1124\/jpet.122.001462","article-title":"Metabolic stability of the demyelination Positron Emission tomography tracer [(18)F]3-Fluoro-4-Aminopyridine and identification of its metabolites","volume":"386","author":"Sun","year":"2023","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111216_bib36","article-title":"Chemical and biophysical characterization of novel potassium channel blocker 3-fluoro-5-methylpyridin-4-amine","volume":"14","author":"Sun","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2026.111216_bib37","article-title":"First evaluation in multiple sclerosis using PET tracer [18F]3F4AP demonstrates heterogeneous binding across lesions","author":"Tiss","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"12","key":"10.1016\/j.neuropharm.2026.111216_bib38","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/nrd2983","article-title":"Voltage-gated potassium channels as therapeutic targets","volume":"8","author":"Wulff","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111216_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0006-3495(76)85663-9","article-title":"Interactions of aminopyridines with potassium channels of squid axon membranes","volume":"16","author":"Yeh","year":"1976","journal-title":"Biophys. J."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111216_bib40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1021\/acs.chemrev.1c00632","article-title":"Biological utility of fluorinated compounds: from materials design to molecular imaging, therapeutics and environmental remediation","volume":"122","author":"Zhang","year":"2022","journal-title":"Chem. Rev."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111216_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13023-021-01694-8","article-title":"Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials","volume":"16","author":"Zhang","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111216_bib42","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12883-021-02405-3","article-title":"3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Neurol."},{"issue":"32","key":"10.1016\/j.neuropharm.2026.111216_bib43","doi-asserted-by":"crossref","first-page":"14463","DOI":"10.1021\/jacs.2c06776","article-title":"C3-Selective trifluoromethylthiolation and difluoromethylthiolation of pyridines and pyridine drugs via dihydropyridine intermediates","volume":"144","author":"Zhou","year":"2022","journal-title":"J. Am. Chem. Soc."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826003916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826003916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:54:37Z","timestamp":1794027277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390826003916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":46,"alternative-id":["S0028390826003916"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111216","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"4-methyl-3-aminopyridine: A novel active blocker of voltage-gated potassium ion channels in the central nervous system","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111216"}}